Q2 EPS Estimates for Immunocore Boosted by Leerink Partnrs

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Immunocore in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.39). The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore's Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($2.22) EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. The business had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.49) earnings per share.

A number of other analysts have also issued reports on the company. Mizuho reduced their target price on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Oppenheimer boosted their price objective on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. lowered their price objective on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.13.

Immunocore Trading Down 3.4%

IMCR traded down $0.99 during trading on Monday, reaching $28.55. The company had a trading volume of 541,139 shares, compared to its average volume of 429,159. The firm's 50-day simple moving average is $28.80 and its 200 day simple moving average is $30.11. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -30.05 and a beta of 0.75. Immunocore has a 12-month low of $23.15 and a 12-month high of $58.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMCR. GF Fund Management CO. LTD. bought a new position in Immunocore in the fourth quarter worth $25,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Immunocore during the first quarter worth approximately $225,000. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC increased its stake in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Tema Etfs LLC bought a new stake in shares of Immunocore in the 4th quarter valued at about $330,000. Institutional investors own 84.50% of the company's stock.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is currently owned by corporate insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.